BETHESDA, Md., Sept. 8, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) will present new clinical data on the possible inter-relationships of XMRV positivity/chronic fatigue syndrome/Ampligen® responsiveness at the 1st International Workshop on XMRV being held at the National Institutes of Health in Bethesda, MD, on September 7 and 8, 2010.
